Welcome to our dedicated page for SS Innovations SEC filings (Ticker: SSII), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
SS Innovations International Inc. (Nasdaq: SSII) files reports and disclosures with the U.S. Securities and Exchange Commission as a registrant with common stock listed on The Nasdaq Stock Market LLC. These SEC filings provide detailed information about the company’s operations in surgical robotics, including its SSi Mantra surgical robotic system and SSi Mudra surgical instruments.
On this page, you can review SSII’s periodic and current reports, such as Form 10-Q quarterly reports and Form 8-K current reports. In its filings and related press releases, SS Innovations has discussed revenue from system sales, instrument sales, warranty sales, and lease income, as well as information about installations of the SSi Mantra system and the cumulative number of surgeries performed. Filings also reference clinical and regulatory milestones, including a human factors validation study for the SSi Mantra at Johns Hopkins Hospital and plans for a 510(k) premarket notification to the U.S. Food and Drug Administration.
SS Innovations’ Form 8-K filings frequently incorporate press releases as exhibits, covering topics such as financial results, telesurgery achievements using the SSi Mantra and the SSi Mantra Tele Surgeon Console, executive appointments, and participation in investor conferences. These documents also confirm that the company’s common stock trades under the symbol SSII and that it is incorporated in Florida with principal executive offices in Gurugram, Haryana, India.
Stock Titan’s SEC filings page for SSII is designed to surface these regulatory documents alongside AI-powered summaries that explain key points in plain language. Users can quickly scan new 8-Ks, 10-Qs, and other filings, and identify disclosures related to revenue composition, operating performance, regulatory progress for the SSi Mantra system, and other material events affecting SS Innovations International Inc.
SS Innovations International, Inc. filed an 8-K to share a press release about its vision for new surgical robotic technologies unveiled at the Global Multi-Specialty Robotic Surgery Conference (SMRSC 2026) in New Delhi, India, which the Company recently hosted.
The Company highlighted four main innovations under development: the SSi Vimana Aero drone-based surgical system, the SSi Avtara humanoid surgical platform, the SSi Operion mobile operating room, and new single-arm robotic endoscopy and ultrasound assist carts. These concepts emphasize remote, mobile and teleoperated care in challenging environments.
At SMRSC 2026, more than 1,600 in-person and 1,800 virtual participants from 19 nations attended. Expert physicians performed 10 live telesurgeries and 13 live robotic surgeries using the Company’s existing SSi Mantra system across multiple specialties. The filing also reiterates standard forward-looking statement cautions.
SS Innovations International, Inc. Chairman and CEO Sudhir Srivastava reported an indirect transfer of 10,000 shares of common stock as a bona fide gift. The shares were held by Sushruta Pvt. Ltd., an entity in which he has a controlling interest.
Following this non-market gift transaction, entities associated with Srivastava indirectly hold 109,585,767 shares of SS Innovations common stock. The filing reflects a routine personal transfer with no sale proceeds or open-market trading activity.
SS Innovations International, Inc. is hosting the Global Multi-Specialty Robotic Surgery Conference (SMRSC 2026) in New Delhi, India from April 9–11, 2026. This third installment will gather surgeons, innovators and healthcare leaders to discuss the future of robotic and minimally invasive surgery.
Attendance is expected to exceed last year’s event, which drew more than 1,400 in-person attendees and 600 virtual participants from 17 nations. The conference will feature live telesurgeries, robotic surgeries, technology demonstrations and expert panels. The company highlights its SSi Mantra surgical robotic system, which has been clinically validated in India across more than 100 types of procedures.
SS Innovations International, Inc. insider Barry F. Cohen, COO – Americas and director, tendered 19,000 shares of common stock at a value of $5.58 per share to a non‑affiliated third-party lender. The shares were used to satisfy principal and interest owed on a $100,000 promissory note. Following this non‑market restructuring transaction, Cohen directly holds 7,780,088 shares of SS Innovations common stock.
SS Innovations International, Inc. director and COO - Americas Barry F. Cohen reported a bona fide gift of 7,000 shares of Common Stock. This non-cash transfer reduced his directly held position to 7,799,088 shares, indicating a routine personal/shareholder gifting event rather than a market sale.
SS Innovations International, Inc. Chairman and CEO Sudhir Srivastava reported a bona fide gift of 246,000 shares of common stock on behalf of an affiliated entity. The shares were held indirectly through Sushruta Pvt. Ltd., in which he has a controlling interest.
After this gift transfer, the filing shows 109,595,767 shares of common stock still reported as owned indirectly. Because this was a gift with no sale proceeds and represents a small portion of the reported holdings, it reflects a non-market, estate or relationship-driven transfer rather than a trading decision.
SS Innovations International, Inc. filed an amendment to its annual report for the year ended December 31, 2025. The amendment adds Exhibit 97.1, a Clawback Policy, to the exhibits list and includes new Section 302 and 906 officer certifications. The company states the amendment does not change any previously reported financial results or other disclosures in the original annual report.
SS Innovations International, Inc. reported new regulatory approvals for its SSi Mantra surgical robotic system in Colombia, Oman, Sri Lanka and Kenya, expanding its addressable markets in Latin America, the Middle East, Africa and South Asia. The system now has regulatory clearance in eleven countries, including India and the United Arab Emirates. As of December 31, 2025, SSi Mantra’s installed base totaled 168 systems across ten countries, with 7,885 cumulative surgeries performed, including 390 cardiac procedures and 121 pediatric surgeries, plus more than 150 telesurgeries. The company also stated it anticipates U.S. FDA review of its 510(k) submission to be completed by mid‑2026 and believes it can obtain European Union CE marking in 2026.
SS Innovations International, Inc. chairman and CEO Sudhir Srivastava reported a bona fide gift of 10,000 shares of common stock. The shares were held indirectly through Sushruta Pvt. Ltd., in which he has a controlling interest. This was a transfer without sale proceeds, not an open-market trade. Following the gift, indirect holdings reported in this filing total 109,841,767 shares, indicating the transaction is small relative to his overall position.